利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.013 seconds)

    3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives
    1.
    发明申请
    3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives 失效
    3-硫代 - [1,2,4] - 恶二嗪-5-酮衍生物

    公开(公告)号：US20020061883A1

    公开(公告)日：2002-05-23

    申请号：US09965874

    申请日：2001-09-28

    Applicant: American Home Products Corporation

    Inventor： Hassan M. Elokdah ,  Theodore S. Sulkowski

    IPC: A61K031/5395 ,  C07D273/04

    CPC classification number: C07D273/04

    Abstract: 1 wherein R is alkyl, alkenyl, or alkynyl; R1 and R2 are each independently hydrogen alkyl, or aryl; and Ar is phenyl, indanyl, benzhydryl, or phenyl, substituted with one or more groups selected from the group consisting of halogen, alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aroyloxy.

    Abstract translation: 其中R是烷基，烯基或炔基; R 1和R 2各自独立地为烷基或芳基; 并且Ar是被一个或多个选自卤素，烷基，全氟烷基，低级烷氧基，全氟烷基烷氧基，二烷基氨基和芳酰氧基的基团取代的苯基，茚满基，二苯甲基或苯基

    CRF receptor antagonists and methods relating thereto
    5.
    发明申请
    CRF receptor antagonists and methods relating thereto 失效
    CRF受体拮抗剂及其相关方法

    公开(公告)号：US20020032194A1

    公开(公告)日：2002-03-14

    申请号：US09861472

    申请日：2001-05-18

    Inventor： Mustapha Haddach

    IPC: A61K031/549 ,  A61K031/5395 ,  A61K031/53

    CPC classification number: C07D487/16 ,  C07D498/16

    Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: 1 including stereoisomers and pharmaceutically acceptable salts thereof, wherein m, R, R1, R2, A, and X are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

    Abstract translation: 公开了CRF受体拮抗剂，其可用于治疗各种疾病，包括治疗在温血动物（例如中风）中表现出CRF过度分泌的病症。 本发明的CRF受体拮抗剂具有以下结构：包括立体异构体及其药学上可接受的盐，其中m，R，R 1，R 2，A和X如本文所定义。 还公开了含有CRF受体拮抗剂与药学上可接受的载体的组合物，以及其用途的方法。

    Arthropodicidal carboxanilides
    8.
    发明申请
    Arthropodicidal carboxanilides 失效
    节肢动物杀虫甲酰苯胺

    公开(公告)号：US20030139397A1

    公开(公告)日：2003-07-24

    申请号：US10220446

    申请日：2002-08-28

    Inventor： David Walter Piotrowski

    IPC: A61K031/549 ,  A61K031/541 ,  A61K031/5395 ,  A61K031/5377 ,  A61K031/506 ,  A61K031/444 ,  C07D417/02 ,  C07D43/02 ,  C07D413/02

    CPC classification number: C07D253/06 ,  A01N43/707 ,  A01N43/90 ,  A01N47/02 ,  A01N47/16 ,  C07D239/20 ,  C07D239/70 ,  C07D253/10 ,  C07D273/00 ,  C07D273/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04

    Abstract: Compounds of Formula (I), and their N-oxides and agriculturally suitable salts, are disclosed which are useful as arthropodicides wherein A is H; E is H or C1-C3 alkyl; or A and E can be taken together to form nullCH2null, nullCH2CH2null, nullOnull, nullSnull, nullS(O)null, nullS(O)2null, nullNR8null, nullOCH2null, nullSCH2null, nullN(R8)CH2null, substituted nullCH2null and substituted nullCH2CH2null, the substituents independently selected from 1-2 halogen and 1-2 methyl; W is N or CR4;X is CR5R6, O, S, NR7 or a direct bond, provided that when W is N, then X is other than a direct bond; Y is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C3 alkylsulfonyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, NR9R10, NnullCR11R12, OR7, COR13, CO2R14 or C1-C6 alkyl substituted by at least one group selected from halogen, C1-C3 alkoxy, CN, NO2, S(O)1R15, COR13, CO2R14 and optionally substituted phenyl; Z is O or S; and R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, G, n and r are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula (I) and a method for controlling arthropods which involves contacting the arthropods or their environment with an effective amount of a compound of Formula (I).

    Abstract translation: 公开了式（I）化合物及其N-氧化物和农业上合适的盐，其可用作其中A为H的杀虫剂; E是H或C 1 -C 3烷基; 或者A和E可以一起形成-CH 2 - ， - CH 2 CH 2 - ， - O - ， - S - ， - S（O） - ， - S（O）2 - ， - NR 8 - ， - OCH 2 - SCH 2 - ， - N（R 8）CH 2 - ，取代的-CH 2 - 和取代的-CH 2 CH 2 - ，独立地选自1-2个卤素和1-2个甲基的取代基; W是N或CR4; X是CR5R6，O，S，NR7或直接键，条件是当W是N时，X不是直接键; Y是H，C1-C6烷基，C2-C6烯基，C2-C6炔基，C1-C3烷基磺酰基，C3-C6环烷基，C3-C6环烷基烷基，NR9R10，N = CR11R12，OR7，COR13，CO2R14或C1-C6烷基 被选自卤素，C 1 -C 3烷氧基，CN，NO 2，S（O）1 R 15，COR 13，CO 2 R 14和任选取代的苯基中的至少一个基团取代; Z是O或S; 并且R 2，R 3，R 4，R 5，R 6，R 7，R 8，R 9，R 10，R 11，R 12，R 13，R 14，R 15，G，n和r如本公开中所定义。 也披露了

Patent Agency Ranking